Insmed (INSM) Long-Term Investments (2021 - 2022)

Insmed (INSM) recorded quarterly Long-Term Investments of $9.8 million in Q2 2022, down 66.96% quarter-over-quarter from $29.6 million in Q1 2022.

Insmed (INSM) Long-Term Investments (2021 - 2022) Analysis & Trends

Insmed's Long-Term Investments history runs 2 years deep, the most recent figure standing at $9.8 million for Q2 2022.

In Q2 2022, Long-Term Investments changed N/A year-over-year to $9.8 million; the TTM figure through Jun 2022 stood at $9.8 million (changed N/A YoY), while the FY2021 annual figure was $50.0 million, changed N/A from the prior year.
Long-Term Investments was $9.8 million for Q2 2022 at Insmed, down from $29.6 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $50.0 million in Q4 2021 to a low of $9.8 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	5.75 Bn
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Insmed	19.79 Bn	18.57 Bn	258.54 Mn	-

Download Data